Rachel A Burga1,2,3, Shabnum Patel1,3, Catherine M Bollard1,4,5,3, Conrad Russell Y Cruz1,4,5,3, Rohan Fernandes1,4,6,2. 1. Institute for Biomedical Sciences, The George Washington University, Washington, DC, USA. 2. The Sheikh Zayed Institute for Pediatric Surgical Innovation, Children's National Health System, Washington, DC, USA. 3. Center for Emerging Technologies in Immune Cell Therapy, Children's National Health System, Washington, DC, USA. 4. Department of Pediatrics, The George Washington University, Washington, DC, USA. 5. Center for Cancer & Immunology Research, Children's National Health System, Washington, DC, USA. 6. Department of Radiology, The George Washington University, Washington, DC, USA.
Abstract
AIM: To engineer a novel nanoimmunotherapy comprising Prussian blue nanoparticles (PBNPs) conjugated to antigen-specific cytotoxic T lymphocytes (CTL), which leverages PBNPs for their photothermal therapy (PTT) capabilities and Epstein-Barr virus (EBV) antigen-specific CTL for their ability to traffic to and destroy EBV antigen-expressing target cells. MATERIALS & METHODS: PBNPs and CTL were independently biofunctionalized. Subsequently, PBNPs were conjugated onto CTL using avidin-biotin interactions. The resultant cell-nanoparticle construct (CTL:PBNPs) were analyzed for their physical, phenotypic and functional properties. RESULTS: Both PBNPs and CTL maintained their intrinsic physical, phenotypic and functional properties within the CTL:PBNPs. CONCLUSION: This study highlights the potential of our CTL:PBNPs nanoimmunotherapy as a novel therapeutic for treating virus-associated malignancies such as EBV+ cancers.
AIM: To engineer a novel nanoimmunotherapy comprising Prussian blue nanoparticles (PBNPs) conjugated to antigen-specific cytotoxic T lymphocytes (CTL), which leverages PBNPs for their photothermal therapy (PTT) capabilities and Epstein-Barr virus (EBV) antigen-specific CTL for their ability to traffic to and destroy EBV antigen-expressing target cells. MATERIALS & METHODS:PBNPs and CTL were independently biofunctionalized. Subsequently, PBNPs were conjugated onto CTL using avidin-biotin interactions. The resultant cell-nanoparticle construct (CTL:PBNPs) were analyzed for their physical, phenotypic and functional properties. RESULTS: Both PBNPs and CTL maintained their intrinsic physical, phenotypic and functional properties within the CTL:PBNPs. CONCLUSION: This study highlights the potential of our CTL:PBNPs nanoimmunotherapy as a novel therapeutic for treating virus-associated malignancies such as EBV+ cancers.
Entities:
Keywords:
Prussian blue nanoparticles; antigen-specific T cells; cell nanoparticle construct; cytotoxic T lymphocyte; immunotherapy; nanoimmunotherapy; photothermal therapy
Authors: Ellen R Goldman; Eric D Balighian; Hedi Mattoussi; M Kenneth Kuno; J Matthew Mauro; Phan T Tran; George P Anderson Journal: J Am Chem Soc Date: 2002-06-05 Impact factor: 15.419
Authors: Edward R Flynn; H C Bryant; Christian Bergemann; Richard S Larson; Debbie Lovato; Dmitri A Sergatskov Journal: J Magn Magn Mater Date: 2007-04 Impact factor: 2.993
Authors: Jennifer M Vojtech; Juliana Cano-Mejia; Matthieu F Dumont; Raymond W Sze; Rohan Fernandes Journal: J Vis Exp Date: 2015-04-28 Impact factor: 1.355
Authors: Roberta Polak; Rosanna M Lim; Marisa M Beppu; Ronaldo N M Pitombo; Robert E Cohen; Michael F Rubner Journal: Adv Healthc Mater Date: 2015-11-30 Impact factor: 9.933
Authors: Albert J Swiston; Jonathan B Gilbert; Darrell J Irvine; Robert E Cohen; Michael F Rubner Journal: Biomacromolecules Date: 2010-07-12 Impact factor: 6.988
Authors: Catherine M Bollard; Laura Aguilar; Karin C Straathof; Benedikt Gahn; M Helen Huls; Alexandra Rousseau; John Sixbey; M Victoria Gresik; George Carrum; Melissa Hudson; Dagmar Dilloo; Adrian Gee; Malcolm K Brenner; Cliona M Rooney; Helen E Heslop Journal: J Exp Med Date: 2004-12-20 Impact factor: 14.307
Authors: Juliana Cano-Mejia; Michelle L Bookstaver; Elizabeth E Sweeney; Christopher M Jewell; Rohan Fernandes Journal: Biomater Sci Date: 2019-04-23 Impact factor: 6.843